GSK's Specialty Medicines drive a confident Q1
GSK (LON:GSK) reported Q1 sales of £7.6bn, with Specialty Medicines, the group's highest-growth engine, rising 14% To £3.2bn. The performance gives management the confidence to reiterate full-year 2026 guidance at constant exchange rates. Shares trade at 2025.0p, up 0.45% In early dealing.
Lloyds doubles down on guidance as profit surges
Lloyds Banking Group (LON:LLOY) posted statutory profit before tax of £2bn For the three months to 31 March, up sharply from £1.5bn A year earlier, as net interest income and other income both strengthen. Return on tangible equity reaches 17.0%, and the bank reiterates its full-year 2026 guidance in full. The stock adds 0.46% To 97.95p.
AstraZeneca holds its line on revenue and earnings targets
AstraZeneca (LON:AZN) reported Q1 total revenue of $15,288m, an 8% Increase year-on-year, and reconfirms its full-year 2026 guidance of mid-to-high single-digit total revenue growth alongside low double-digit Core EPS growth, both at constant exchange rates. The stock edges back 0.52% To 13,900.0p, a modest pullback against an otherwise firm set of numbers.
Prudential's new business profit climbs 10% in Q1
Prudential (LON:PRU) reported TEV new business profit of $686m For the first quarter, up 10% On a constant exchange rate basis versus the same period last year. The insurer says it remains confident of delivering double-digit growth across 2026, keeping its targets firmly intact. Shares tick up 0.18% To 1,119.0p.
Haleon lines up analyst session alongside Q1 update
Haleon (LON:HLN) released its Q1 trading statement for the year ending 31 December and schedules a presentation and Q&A with CEO Brian McNamara and CFO Dawn Allen at 9:00am BST. The consumer health group's shares slip 0.17% To 349.7p Ahead of the briefing.
Ondine raises £5m to advance FDA filing
Ondine Biomedical (LON:OBI) raised £5m Through the issue of 41.67m New shares at 12p, with proceeds directed toward NDA preparation, GMP commercial-scale production, and ongoing FDA engagement. The placing extends the company's cash runway to early Q4 2026. Shares trade at 13.0p, up 4.0% On the day.
Halfords eyes upper end of profit consensus
Halfords issued a trading update ahead of its FY26 results, reporting group like-for-like sales growth of 4.8% And guiding that full-year underlying profit before tax is expected around the upper end of the £36m to £41.2m Consensus range. The update points to sustained consumer demand for the auto and cycling retailer's services and products.
Frasers Group adds two designer outlets to its estate
Frasers Group announced the acquisition of York Designer Outlet and East Midlands Designer Outlet, bringing almost 7.8m Combined annual visitors into its property and retail platform. The deal broadens the group's physical retail footprint beyond its core sports and lifestyle fascias into the premium outlet channel.
Döhler tables 305p cash offer for Treatt
Döhler Finance Management B.V. Launches a recommended all-cash offer for Treatt at 305p per share, valuing the flavours and fragrance ingredients specialist at approximately £183m. The deal is expected to complete in Q3 2026, subject to shareholder and regulatory approvals.
